Australian (ASX) Stock Market Forum

FER - Fermiscan Limited

Jump to new
the reson is simpel; we don't want to put fermiscan in doubtful daylight...:rolleyes:

no not really ... the fact is that we all know that there is some competition
there is also a breath test in developing; and it is obvious that the best test will have the better outcome....
but that's a long way away ... not that fermiscan will do badly ... not at all
the accuraccy so far is very good

see first off all fermiscan is leading the race in developing a commercial product ( specially with all the patents in place all over the world; and a strong grip on the asain market)

second ...''IF'' ...let say all three test are beeing commercialised at the same moment than still it would take years to take over the worldmarket
__(''for the best test''... ??? only time, years will tell which one that is; specially on claming that a test can detect breast cancer before there is actually a breastcancer lump... so in fact detecting breastcancer cells! )___


and as last remark... yes it would be great if fermiscan could secure a monopoly position... but which market , company still has that privellige of a monopoly.

i'm im very happy about the fact that you came on the forum and challenge our invesment because it make us think about our investment and tick the boxes if the investment is still of good value

no dought here that fermiscan is gonna do well
cheers
 
Agree. Good to hear about competitor solutions in the pipelines.

I still have faith in Fermi due to iminent commercial launch and lead to market advantage, not to mention high quality of results versus other options in the market today.

This week is crunch time and the biggest week in Fermi's existence.

Quite a few people (me included) have been tipping a full trial completion announcement either at the AGM or before. Fingers crossed this happens.

It's one thing for the share price to ride the roller coaster due to announcements relating to originally developing the solution, then getting patents, achieving additional investor funding, doing trials, winning awards and creating all the necessary hype, but the final truth will be made available when the 2000 patient trial is completed 'successfully' and commercialisation details are released.

I'm still a believer....
 
Hey Drasic that's very encouraging. We have seen some good support the last few days so here's hoping results are not too far away and the market stays sensible.:)
 
morton_mains said:
This was on our radio (in NZ) couple days ago -surprised not mentioned on AussieStockF yet as possible competition for FER

http://www.dailymail.co.uk/pages/live/articles/news/news.html?in_article_id=562308&in_page_id=1770

And they wouldn't need a synchrotron
Click to expand...

Obviously as a holder I am biased, but the first thing that came to mind was that drawing blood is invasive and there may be issues with either race or religions regarding taking blood among other things like transport etc.
Just my:2twocents worth.:)
 
one thing that i forgot to mention ...and to me the biggest addvantage over the other diagnostic tools is that the hair has a memory....
it is able to display over a time interval (lenght of the hair)
this realy makes fermiscan a whole other kettle of fish
 
This is great news. Now onto commercialisation and the reward for all of us who have held.:D

Fermiscan successfully completes validation trial
Fermiscan Holdings (ASX: FER), which is commercialising a non-invasive test for breast cancer, today announced the successful completion of its 2,000 patient trial, which commenced in 2007.
This large scale trial was designed to compare results from the current breast cancer screening methods of mammography and ultrasound (and any subsequent biopsy and pathology results) with the Fermiscan test. The trial confirmed the ability of the Fermiscan test to detect the presence of breast cancer, using x-ray diffraction of hair.
Accuracy of 69% was achieved, and by exclusion of patients whose hair was subsequently analysed and independently confirmed as having been treated and damaged, the accuracy is 75%. The company’s validation phase is now complete.
In light of the positive results from the trial and continuous progressive improvement to operations, Fermiscan plans to progress to commercialisation of the test in Australia in 2008.
Validation phase and trial outcomes include:
•
Overall accuracy level of the Fermiscan test in the 2,000 patient trial was 69% (75% after exclusion of damaged hair) - see attached summary tables
•
Correct diagnosis of almost 1500 women as negative for breast cancer and 20 patients correctly as positive for breast cancer
•
Correctly identified as negative for breast cancer 80 per cent of patients referred for a biopsy as a result of mammography. This highlights the potential value of the test in conjunction with current screening methods
•
13 patients found to be positive for breast cancer by a mammogram and biopsy were missed by the Fermiscan test. This is believed to be due to damage to hair from treatments not identified by fluorescence screening and/or biological variation. The accuracy of the test can be affected by hair treatments such as perming, dyeing and straightening, which can be overcome in most cases by using new growth of the hair (approximately 4 weeks required)
•
The accuracy of the test in a commercial use is expected to significantly improve as women will prepare for the test by ensuring they have undamaged new growth of hair for testing. During the trial this could not take place as patients had no advance notice of the test and the requirements
•
The value of the test for women of all ages was confirmed with patients covering a wider age group than current screening recommendations
•
Optimisation of synchrotron beam-lines to significantly improve high resolution images
•
Automation improvements to extend commercial capacity
•
Significant progress made towards securing access to synchrotron beam lines in key countries
•
Secured the support of key medical and patient advocate groups
Fermiscan Managing Director Mr David Young said, “We are extremely pleased to have validated the commercial potential of the Fermiscan test. Given its non-invasive nature, suitability for women off all ages and comparative accuracy relative to other screening methods currently available, the commercial potential is significant.”
Fermiscan will now commence commercial development in Australia and overseas. This development path includes:
•
Further analysis of the data from the 2,000 patient trial to refine the analysis methodology and criteria to further improve the accuracy of the test
•
Commencement in the next few months of approved clinical research with leading hospitals in Italy and Japan as well as the Ashford Cancer Centre, a leading Cancer Clinic in Adelaide. Fermiscan plans to gather data from patients with a range of breast cancers (and other cancer patients) to allow further refinement and improvement of the test
•
Securing time on third generation synchrotron beam lines in key countries
•
Developing key statistical findings and communication messages
•
Implementing a detailed Research & Development plan to allow further development of Fermiscan’s technology
•
Plans to progress to commercialisation of the test in Australia in 2008
•
Commencing regulatory approval processes internationally
Sue Murray, the CEO of the National Breast Cancer Foundation, said, “Research underpins all the advances in breast cancer diagnosis, treatment and on-going care. Breast cancer is most effectively treated when detected early and this new technology from Fermiscan is showing very strong results.
Further testing will confirm the benefits and potentially offer improved survival for women of all ages. We look forward to the results from the clinical research to be undertaken both overseas and in Adelaide.”
Fermiscan Managing Director Mr David Young said “We are pleased to be moving into this exciting phase of development. The support we have had from the hospitals and clinics involved in the trial has been very encouraging and I would also like to thank all the patients who have participated in the trial. We look forward to this continuining support to improve the health outcomes of women worldwide as we develop our scientific, medical and commercial capability”.
 
i didn't expect they would be finisched ... i had a word with fermiscan 2 days ago and tehy sad that the test wasn't finisched yet....:rolleyes:
clearly they didn't want me to know :cool:
i very happy this will be a day to remember...

grace... go for it girl ...get that first possition
 
............and in response the share price reacts by going.......................(drum roll).....down 10%!
WTF!:dunno:
 
some people were iger to get out after a long wait and the big investors are in a meeting
the day isn't over yet....
 
Hi Drasicjazz,

do you have any idea as to what we should expect to come of the "big investor" meeting being held today?:)
 
Well, I'm pleased with the results. Market might take a little time to absorb by the looks of it.

I remember when Cochlear came asking for $2.00 for their ear implants, and I for one was very hesitant. Look at them now.

Give it time.....a bit of media attention now will help. Expect it in newspapers tomorrow, perhaps the news tonight if we are lucky.
 
the agm... you mean
well as we are done guessing if fermiscan is feasible or not
i'll expect a more sollid buy-volume rise and fishing the last standing sell offers
startingtoday and the coming weeks as now fermiscan will be open and expose theimself for commercialising
todays price is only half of what it was last year ...
and now we have much better cards in hand ...

1 and 1 is two ...no matter how you look at it
relax and let the sp do it work, it will get there
regards
 
Correctly identified as negative for breast cancer 80 per cent of patients referred for a biopsy as a result of mammography. This highlights the potential value of the test in conjunction with current screening methods

This is a definite standout for the benefits of the Fermiscan product. If they spare women the fear and apprehension inthe build up waiting for a biopsy, this is amazing.
 
My question would be how common are the machines (x-ray synchrotron) that are used to perform the hair tests?
If this is not a machine that your average pathology lab would have, then there may be issues in obtaining use of such machines, which may have waiting lists to perform all sorts of tests?

Other than that, interesting price action today on what for all purposes is quite a significant announcement- ie the confirmation of the viability of the test in detecting breast cancer.
With the sell side now larger than the buy side, maybe just bigger holders trying to scare the smaller holders into selling out.
Sure the SP has had good gains in the last week, but SP nothing like the highs of one year ago.
 
Todays announcement was definitely positive. More good media attention will hopefully follow.

The share price should have taken off today based on the trial being completed and positive. This smells very much like one of the larger shareholders is selling to get some cash. Perhaps they are not in for the long term or have financial problems, and have been waiting for the buyers to line up after a good announcement to get the required volumes. Who knows?

I'm surprised there wasn't another big investor out there prepared to buy up some of the stock on offer today? Is the market waiting for more information about the commercialization or perhaps the results of the trial were not as good as they wanted?

Lets hope the Fermi PR manager gets some decent coverage to raise the awareness from large and small investors asap. Need to strike whilst the irons hot!
 
shaunm said:
Correctly identified as negative for breast cancer 80 per cent of patients referred for a biopsy as a result of mammography. This highlights the potential value of the test in conjunction with current screening methods

This is a definite standout for the benefits of the Fermiscan product. If they spare women the fear and apprehension inthe build up waiting for a biopsy, this is amazing.
Click to expand...

Not only that, but this test (FERMISCAN) should be considered as the screening tool for women under 40, just as mammography is for women over 50. Therefore, medicare consideration should be given in order to reduce cost to patient.
 
Just saw a highlight for the channel seven news for tonight, a breast cancer test you can do at home. I assume it is Fermiscan. They showed cutting some hair off behind the ear. Will be watching out for it at 6.00pm!
 
grace i missed the 6 o clock news
was fermiscan on it? i can't semm to find any hit ion the 7 news website
 
Top